2060 - North Sydney - Mater Hospital (WITHDRAWN)2065 - St Leonards - GenesisCare North Shore Private Hospital (WITHDRAWN)2640 - Albury - Border Medical Oncology Research Unit (WITHDRAWN)

TAS7000 - Hobart - ICON Cancer Care Hobart (WITHDRAWN)

NCT05216432

A First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, As a Single Agent in Advanced Solid Tumor Patients and in Combination with Fulvestrant in Patients with Advanced Breast Cancer (RLY-2608-101)

NCT05123482

A Phase I/IIa Multi-center, Open-label Master Protocol Dose Escalation and Expansion Study of AZD8205 as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors (BLUESTAR) (D6900C00001)

QLD4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (WITHDRAWN)

NCT05086692

A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors (ABILITY-1)

NCT05081609

IL Believe: A Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study to Investigate the Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab, TransCon TLR7/8 Agonist, or Other Anticancer Therapies, in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies (IL-Believe)

5065 - Toorak Gardens - Burnside War Memorial Hospital (TERMINATED)

NCT04986852

A Phase II, Open-Label, Multicenter Study of Olinvacimab in Combination With Pembrolizumab in Patients With Metastatic Triple-Negative Breast Cancer (KEYNOTE-C14)

NCT04947189

4CAST: A Phase 1b Dose Exploration and Dose Expansion, Open-label, Single-centre Study Evaluating the Safety and Efficacy of INO-464 in Combination With Chemotherapy in Patients With metASTatic Breast Cancer

NCT04895709

A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors (CA052-002)

NCT04862663

A Phase Ib/III, Open-label, Randomised Study of Capivasertib Plus CDK4/6 Inhibitors and Fulvestrant Versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292)

2076 - Wahroonga - Sydney Adventist Hospital (WITHDRAWN)2228 - Miranda - Southside Cancer Care Centre (WITHDRAWN)

NCT04802759

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Breast Cancer (MORPHEUS-BREAST CANCER) (CO42867)

NCT04739670

A Single Arm Phase II Trial Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Early Relapsing Metastatic Triple Negative Breast Cancer (BELLA)

NCT04644068

A Modular Phase I/IIa, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (PETRA)

NCT04606446

A PHASE 1/2A DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC, AND ANTI-TUMOR ACTIVITY OF PF-07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS (KAT6)

NSW2050 - Camperdown - Chris O'Brien Lifehouse (TERMINATED)

NCT04585750

A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

NCT03424005

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Treatment Combinations In Patients With Metastatic Breast Cancer (Morpheus-panBC)

ACTRN12625000203459

An open-label, multicenter, Phase I/IIa study assessing the safety and efficacy of EGFR targeted EDVsTM carrying cytotoxic drug PNU-159682 plus concurrent immunomodulatory adjuvant non-targeted EDVs carrying a-galactosyl ceramide in subjects with advanced EGFR-expressing cancers who have failed second-line therapy or where first- and/or second-line therapy is not appropriate (EGFR EDV-D682/GC Trial) (ENG19)

ACTRN12624001340527

A Phase 1b, Multi-centre, Open-label, Randomized Study to Evaluate the Safety, Tolerability, and Clinical Activity of Combining Paxalisib with Olaparib or Pembrolizumab/Chemotherapy in Patients with Advanced Breast Cancer (PaxPlus-ABC)

ACTRN12622000016730

Addition of prochlorperazine to paclitaxel, trastuzumab, and pertuzumab for previously untreated HER2-positive metastatic breast cancer: a phase 1 dose de-escalation study (HER2Pro-1B)

ACTRN12621001419853

A Phase 1 Dose Escalation and Dose Expansion Open-label, Multicenter, Study of OP-1250 in Combination with the CDK4/6 Inhibitor Palbociclib in Adult Subjects with Advanced or Metastatic HR-positive, HER2-negative Breast Cancer (OP-1250-002)

NCT05852691

A Phase II, Multicenter, Randomized, Double-Blind Study of Tobemstomig/RO7247669 Combined With Nab-Paclitaxel Compared With Pembrolizumab Combined With Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (CO44194)

NCT03906331

Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

oestrogen axis	39%
ER	35%
CDK4	32%
CDK6	27%
PD-1/PD-L1	26%
PD-1	20%
PI3K alpha	18%
ERBB2	17%
Trop2	12%
CDK4 selective	9%
mTOR	9%
mTORC1	9%
CDK2	8%
AKT	8%
PD-L1	8%
VEGF	6%
PARP	6%
PI3K	5%
mTORC2	5%
PARP1-selective	5%
TIGIT	3%
ERBB3	3%
EGFR	3%
KAT6	3%
FR-alpha	3%
hGIIA-vimentin	2%
Bcl2	2%
ER alpha	2%
VEGFA	2%
B7H3	2%
Nectin-4	2%
MET	2%
SMO	2%
CD39	2%
B7H4	2%
IL-2	2%
TLR7/TLR8	2%
VEGFR2	2%
CYP17A1	2%
androgen axis	2%
CCR8	2%
CDK7	2%
TP53	2%
TP53 Y220C	2%
CD40	2%
IL-6	2%
LIV1	2%
PI3K delta	2%
LAG3	2%
RET	2%

ARTICANZ - Beta (ver 0.91)

Search results

Breast / Breast - Metastatic

Filters